Natl Sci Open
Volume 1, Number 1, 2022
Special Topic: COVID-19: Virus, Immunity and Vaccines
|Number of page(s)||6|
|Section||Life Sciences and Medicine|
|Published online||24 March 2022|
Cell-in-cell: an Emerging Player in COVID-19 and Immune Disorders
Beijing Institute of Biotechnology, Academy of Military Medical Sciences, 20 Dongda Street, Beijing 100071, China
2 Research Unit of Cell Death Mechanism, Chinese Academy of Medical Science, 2020RU00920 Dongda Street, Beijing 100071, China
* Corresponding author. E-mail: email@example.com
Received: 1 December 2021
Accepted: 30 December 2021
Cell-in-cell is a unique phenomenon mostly documented in human cancer tissues. A recent study demonstrated that cell-in-cell might promote lymphopenia by internalizing and killing immune cells in COVID-19, which implicates cell-in-cell as an emerging player in a broader spectrum of pathological processes, such as immune dysregulation.
Key words: cell-in-cell / cell death / COVID-19 / lymphopenia / immune dysregulation
© The Author(s) 2022. Published by China Science Publishing & Media Ltd. and EDP Sciences.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.